4-aminopyridine has been researched along with Acute Relapsing Multiple Sclerosis in 15 studies
Excerpt | Relevance | Reference |
---|---|---|
"At the end of the treatment, EDSS, fatigue and depression scores were further evaluated." | 2.71 | Fatigue in multiple sclerosis: multidimensional assessment and response to symptomatic treatment. ( Alfonsi, E; Bergamaschi, R; Callieco, R; Candeloro, E; Cosi, V; Romani, A, 2004) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 3 (20.00) | 29.6817 |
2010's | 10 (66.67) | 24.3611 |
2020's | 2 (13.33) | 2.80 |
Authors | Studies |
---|---|
Bellinvia, A | 1 |
Portaccio, E | 1 |
Amato, MP | 1 |
Shi, J | 1 |
Wu, X | 1 |
Chen, Y | 1 |
van Munster, CEP | 1 |
Kaya, L | 1 |
Lam, KH | 1 |
Kalkers, NF | 1 |
Killestein, J | 1 |
Uitdehaag, BMJ | 1 |
Panicucci, E | 1 |
Cohen, M | 1 |
Bourg, V | 1 |
Rocher, F | 1 |
Thomas, P | 1 |
Lebrun, C | 1 |
Arreola-Mora, C | 1 |
Silva-Pereyra, J | 1 |
Fernández, T | 1 |
Paredes-Cruz, M | 1 |
Bertado-Cortés, B | 1 |
Grijalva, I | 1 |
Foschi, M | 1 |
Lugaresi, A | 1 |
Pavsic, K | 1 |
Pelicon, K | 1 |
Ledinek, AH | 1 |
Sega, S | 1 |
Keune, PM | 1 |
Cocks, AJ | 1 |
Young, WR | 1 |
Burschka, JM | 1 |
Hansen, S | 1 |
Hofstadt-van Oy, U | 1 |
Oschmann, P | 1 |
Muenssinger, J | 1 |
Huynh, W | 1 |
Pickering, H | 1 |
Howells, J | 1 |
Murray, J | 1 |
Cormack, C | 1 |
Lin, CS | 1 |
Vucic, S | 1 |
Kiernan, MC | 1 |
Krishnan, AV | 1 |
Gasperini, C | 1 |
Hupperts, R | 1 |
Lycke, J | 1 |
Short, C | 1 |
McNeill, M | 1 |
Zhong, J | 1 |
Mehta, LR | 1 |
Maillart, E | 1 |
Gout, O | 1 |
Lubetzki, C | 1 |
Carpentier, B | 1 |
Nizard, J | 1 |
Kümpfel, T | 1 |
Havla, J | 1 |
Hohlfeld, R | 1 |
Mainero, C | 1 |
Inghilleri, M | 1 |
Pantano, P | 1 |
Conte, A | 1 |
Lenzi, D | 1 |
Frasca, V | 1 |
Bozzao, L | 1 |
Pozzilli, C | 1 |
Romani, A | 1 |
Bergamaschi, R | 1 |
Candeloro, E | 1 |
Alfonsi, E | 1 |
Callieco, R | 1 |
Cosi, V | 1 |
Goodman, AD | 1 |
Cohen, JA | 1 |
Cross, A | 1 |
Vollmer, T | 1 |
Rizzo, M | 1 |
Cohen, R | 1 |
Marinucci, L | 1 |
Blight, AR | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Efficacy and Safety of 4-aminopyridine on Cognitive Performance and Motor Function of Patients With Multiple Sclerosis. Randomized, Blinded, Placebo-controlled Clinical Trial.[NCT02280096] | Phase 2 | 24 participants (Actual) | Interventional | 2014-10-31 | Completed | ||
The Effect of Kinesiotape Applied on Paraspinal Muscles on Balance in Individuals With Multiple Sclerosis[NCT05341895] | 60 participants (Anticipated) | Interventional | 2021-11-22 | Recruiting | |||
Fampyra Outcome Measures Study: a Study of Different Outcome Measures on the Effect of Fampyra[NCT01656148] | Phase 4 | 108 participants (Actual) | Interventional | 2012-06-30 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Measure sustained attention. The CTT uses numbered coloured circles and universal sign language symbols. The circles are printed with vivid pink or yellow backgrounds that are perceptible to colourblind individuals. For the Colour Trails 1 trial, the respondent uses a pencil to rapidly connect circles numbered 1 through 25 in sequence. Less time indicates better performance (min=10, max= 240). (NCT02280096)
Timeframe: 5-8 minutes
Intervention | units on a scale (seconds) (Mean) |
---|---|
4-aminopyridine | 68.91 |
Placebo | 67.3 |
The Fatigue Severity Scale (FSS) is one of the most frequently used inventories for measuring fatigue in people with chronic illnesses. The FSS questionnaire is comprised of nine statements inquiring about the examinee's sleep habits over the preceding week. Ratings are on a 7-point Likert scale, where higher scores indicate how strongly the patient agrees with the nine statements.Scale. Scoring using a bimodal response system or a Likert score with weights assigned to each response choice. Likert or bimodal rating scales with 4 response options. For the Likert Scale: better than usual= 0, no more than usual= 1, worse than usual= 2, much worse than usual= 3. For the bimodal scale: better than usual= 0, no more than usual= 0, worse than usual= 1, much worse than usual= 1. Sum all items for a total score. Score range. Range is 0 -11 for bimodal response format. Interpretation of scores. Higher score indicates more fatigue. Self report scale (NCT02280096)
Timeframe: 10 minutes
Intervention | score on a scale (Mean) |
---|---|
4-aminopirydine | 4.3 |
Placebo | 3.3 |
The Expanded Disability Status Scale (EDSS) is a method of quantifying disability in multiple sclerosis and monitoring changes in the level of disability over time. It is widely used in clinical trials and in the assessment of people with MS. The EDSS scale ranges from 0 to 10 in 0.5 unit increments that represent higher levels of disability. Scoring is based on an examination by a neurologist. The first levels 1.0 to 4.5 refers to people with a high degree of ambulatory ability and the subsequent levels 5.0 to 9.5 refers to the loss of ambulatory ability. It also provides eight subscale measurements called Functional System (FS) scores. The levels of function within each category refer to the eight FS affected by MS: The FS are scored on a scale of 0 (low level of problems) to 5 (high level of problems) to best reflect the level of disability observed clinically. (NCT02280096)
Timeframe: 15-20 minutes
Intervention | score on a scale (Mean) |
---|---|
4-aminopyridine Treatment | 4.6 |
Placebo | 4.04 |
Integrated Program of Neuropsychological Exploration Test Barcelona: Digit Span Forward (DSF), (attention spam and improved scoring metrics significantly enhance the precision of DSF assessments of short-term verbal memory). Digit sequences are presented beginning with a length of two digits and two trials are presented at each increasing list length. Max score 8 and min score 0 digits. Higher scores indicate a better cognitive performance. (NCT02280096)
Timeframe: 7-10 min
Intervention | correct numbers recalled (Mean) |
---|---|
4-aminopyridine | 6.1 |
Placebo | 5 |
The purpose of this test is to assess visual-spatial constructional ability and visual memory. The time required to copy the drawing is recorded. Less time indicates a better performance and more time indicates a worse outcome (min score 60 and max score 300 seconds). (NCT02280096)
Timeframe: 10-15 minutes
Intervention | units on a scale (seconds) (Mean) |
---|---|
4-aminopyridine | 208.6 |
Placebo | 231.2 |
Neuropsychological tests to assess: verbal fluency. Participants have to say as many words as possible from a category in a given time 60 Sec (F, A, S) Max score 72 and min score 19 words. Higher scores indicate a better cognitive performance. (NCT02280096)
Timeframe: 10-15 minutes
Intervention | Correct words (Mean) |
---|---|
4-aminopyridine | 42.09 |
Placebo | 35.5 |
Timed 25 Foot Walk Test (T25-FW). The T25-FW is a quantitative mobility and leg function performance test based on a timed 25-walk. The patient is directed to one end of a clearly marked 25-foot course and is instructed to walk 25 feet as quickly as possible, but safely. The time is calculated from the initiation of the instruction to start and ends when the patient has reached the 25-foot mark. The task is immediately administered again by having the patient walk back the same distance. Patients may use assistive devices when doing this task. TIME LIMIT PER TRIAL (2) 3 minutes (180 seconds) per trial. (NCT02280096)
Timeframe: 5-10 minutes
Intervention | seconds (Mean) |
---|---|
4-aminopyridine | 15.2 |
Placebo | 10.4 |
"Is used primarily to assess perseveration and abstract thinking, allows the clinician to assess the following 'frontal' lobe functions: strategic planning, organised searching, utilising environmental feedback to shift cognitive sets, directing behaviour toward achieving a goal. WCST measures abstract reasoning and ability to alter problem solving strategies. Patients are given 128 response cards and 4 stimulus cards and asked to match each stimulus card to 1 pile of response cards. The patient is not told how to match the cards, only right or wrong to each placement. The examiner may change matching rules during the test. Perseveration errors occur when subject repeats the same error no matter how many times they are told the placement is wrong. Higher scores indicate a worse cognitive performance (min=0-3, max=58-126)" (NCT02280096)
Timeframe: 10-15 minutes
Intervention | score on a scale (Mean) |
---|---|
4-aminopyridine | 19.8 |
Placebo | 22.8 |
Processing speed information (which includes reading, count, and alternation speed). Cards with a different number of stimuli are shown to the patient, who has to read, count, and respond to a change of instructions (alternation). Reading speed (min 12, max 31+ seconds), counting speed (min 14, max 28+ seconds), and alternation speed (min 26, max 56+ seconds) are recorded. Less speed corresponds to a better outcome. (NCT02280096)
Timeframe: 8-10 min
Intervention | seconds (Mean) | ||
---|---|---|---|
Reading speed | Count speed | Alternation speed | |
4-aminopirydine | 28 | 30.5 | 60.3 |
Placebo | 29.6 | 34.2 | 58.8 |
Safety surveillance will be done every two weeks from the beginning of the study, intentionally searching for adverse events (AE). EEG (Diffuse or focal cerebral dysfunction through demonstration of background slowing or presence of epileptiform activity assessed by a neurophysiologist) and laboratory tests (Presence of values higher of the normal value established by local laboratory and related to the administration of treatments), blood and urine samples: creatinine, blood urea nitrogen, total cholesterol, triglycerides, total direct, and indirect bilirubin, alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, creatinine kinase, lactic acid dehydrogenase, amylase and lipase. A complete blood cell count with differentials and a routine urinalysis and urine culture also obtained at each visit, will be done before the patients take 40, 50 and 60 mg/day. The number of participants with abnormal studies were reported. (NCT02280096)
Timeframe: 22 weeks
Intervention | Participants (Count of Participants) | |
---|---|---|
Number of participants with abnormal lab results | Number of participants with abnormal EEG | |
4-aminopyridine Treatment | 1 | 0 |
Placebo | 0 | 0 |
Measures higher-order problem-solving ability. The information it provides is not only useful when assessing frontal lobe damage, but also when evaluating attention disorders and executive functioning difficulties. The administrator arranges red, green, and blue beads on a peg board to match the configuration in the diagram. The patient is asked to replicate the configuration on a second peg board. Scores are calculated for Total Execution Time (since the patient performs the first move until he ends the test), Total Problem-Solving Time (the sum of planning and execution times). Total execution time higher scores indicate a worse outcome (min= 0-78, max=564+ seconds), Total problem-solving time higher scores indicate a worse outcome (min= 0-56, max=500+ seconds). (NCT02280096)
Timeframe: 25-30 minutes
Intervention | seconds (Mean) | |
---|---|---|
Total execution time | Total problem-solving time | |
4-aminopyridine | 296.2 | 363.3 |
Placebo | 367.9 | 426.8 |
Measures higher order problem-solving ability. The information it provides is not only useful when assessing frontal lobe damage, but also when evaluating attention disorders and executive functioning difficulties. The administrator arranges red, green, and blue beads on a peg board to match the configuration in the diagram. The patient is asked to replicate the configuration on a second peg board. Scores are calculated for Total Correct Moves and Total Moves. Total moves: higher scores indicate a worse cognitive performance (min= 0, max=58+); Total correct higher scores indicate a better cognitive performance (min=0, max=10). (NCT02280096)
Timeframe: 25-30 minutes
Intervention | score on a scale (Mean) | |
---|---|---|
Total moves | Correct moves | |
4-aminopyridine | 42.7 | 4 |
Placebo | 50.8 | 3 |
2 reviews available for 4-aminopyridine and Acute Relapsing Multiple Sclerosis
Article | Year |
---|---|
Current advances in the pharmacological prevention and management of cognitive dysfunction in multiple sclerosis.
Topics: 4-Aminopyridine; Adult; Cognition; Cognitive Dysfunction; Humans; Multiple Sclerosis; Multiple Scler | 2023 |
Study on Dalfampridine in the treatment of Multiple Sclerosis Mobility Disability: A meta-analysis.
Topics: 4-Aminopyridine; Disabled Persons; Humans; Immunosuppressive Agents; Mobility Limitation; Multiple S | 2019 |
8 trials available for 4-aminopyridine and Acute Relapsing Multiple Sclerosis
Article | Year |
---|---|
Effects of 4-aminopyridine on attention and executive functions of patients with multiple sclerosis: Randomized, double-blind, placebo-controlled clinical trial. Preliminary report.
Topics: 4-Aminopyridine; Adult; Attention; Disability Evaluation; Double-Blind Method; Executive Function; F | 2019 |
Short-term impact of fampridine on motor and cognitive functions, mood and quality of life among multiple sclerosis patients.
Topics: 4-Aminopyridine; Activities of Daily Living; Adult; Affect; Aged; Cognition; Depression; Exercise Te | 2015 |
Dynamic walking features and improved walking performance in multiple sclerosis patients treated with fampridine (4-aminopyridine).
Topics: 4-Aminopyridine; Adult; Biomedical Research; Delayed-Action Preparations; Exercise Test; Female; Hum | 2015 |
Effect of fampridine on axonal excitability in multiple sclerosis.
Topics: 4-Aminopyridine; Adult; Aged; Axons; Female; Humans; Male; Middle Aged; Multiple Sclerosis, Relapsin | 2016 |
Prolonged-release fampridine treatment improved subject-reported impact of multiple sclerosis: Item-level analysis of the MSIS-29.
Topics: 4-Aminopyridine; Double-Blind Method; Female; Humans; Male; Middle Aged; Multiple Sclerosis, Chronic | 2016 |
Enhanced brain motor activity in patients with MS after a single dose of 3,4-diaminopyridine.
Topics: 4-Aminopyridine; Adult; Amifampridine; Axons; Cross-Over Studies; Double-Blind Method; Electromyogra | 2004 |
Fatigue in multiple sclerosis: multidimensional assessment and response to symptomatic treatment.
Topics: 4-Aminopyridine; Adult; Antidepressive Agents, Second-Generation; Cognition; Depression; Disability | 2004 |
Fampridine-SR in multiple sclerosis: a randomized, double-blind, placebo-controlled, dose-ranging study.
Topics: 4-Aminopyridine; Adult; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration S | 2007 |
Fampridine-SR in multiple sclerosis: a randomized, double-blind, placebo-controlled, dose-ranging study.
Topics: 4-Aminopyridine; Adult; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration S | 2007 |
Fampridine-SR in multiple sclerosis: a randomized, double-blind, placebo-controlled, dose-ranging study.
Topics: 4-Aminopyridine; Adult; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration S | 2007 |
Fampridine-SR in multiple sclerosis: a randomized, double-blind, placebo-controlled, dose-ranging study.
Topics: 4-Aminopyridine; Adult; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration S | 2007 |
5 other studies available for 4-aminopyridine and Acute Relapsing Multiple Sclerosis
Article | Year |
---|---|
Responder rates to fampridine differ between clinical subgroups of MS patients and patient reported outcome influences treatment decision making.
Topics: 4-Aminopyridine; Adult; Clinical Decision-Making; Female; Follow-Up Studies; Humans; Male; Middle Ag | 2020 |
De novo convulsive status epilepticus in patients with multiple sclerosis treated with dalfampridine.
Topics: 4-Aminopyridine; Adult; Female; Humans; Male; Middle Aged; Multiple Sclerosis; Multiple Sclerosis, R | 2019 |
Evaluating dalfampridine for the treatment of relapsing-remitting multiple sclerosis: does it add to the treatment armamentarium?
Topics: 4-Aminopyridine; Clinical Trials as Topic; Cognitive Dysfunction; Cost-Benefit Analysis; Databases, | 2019 |
Favorable outcome of a pregnancy after fampridine exposition during the first month.
Topics: 4-Aminopyridine; Adult; Female; Humans; Multiple Sclerosis, Relapsing-Remitting; Potassium Channel B | 2016 |
[Progress of therapy in patients with multiple sclerosis].
Topics: 4-Aminopyridine; Adrenal Cortex Hormones; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; | 2010 |